| Lin CP |
------>authors3_c=??? ------>paper_class1=1 ------>Impact_Factor=2.245 ------>paper_class3=2 ------>paper_class2=1 ------>vol=18 ------>confirm_bywho=yjchen ------>insert_bywho=liuxx086 ------>Jurnal_Rank=56.7 ------>authors4_c=??? ------>comm_author=1 ------>patent_EDate=None ------>authors5_c=??? ------>publish_day=1 ------>paper_class2Letter=None ------>page2=170 ------>medlineContent= ------>unit=E1400 ------>insert_date=20061213 ------>iam=5 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN=0959-4973 ------>authors_c=??? ------>score=457 ------>journal_name=Anticancer Drugs ------>paper_name=Small molecule c-Myc inhibitor, 10058-F4, inhibits proliferation and downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma ------>confirm_date=20080508 ------>tch_id=091065 ------>pmid=17159602 ------>page1=161 ------>fullAbstract=c-Myc oncogene is critical for the development of hepatocellular carcinoma. Given the successful use of small-molecule inhibitors on cancers, targeting c-Myc with small-molecule inhibitors represents a promising approach. The potential of using small-molecule c-Myc inhibitor, 10058-F4, was evaluated on hepatocellular carcinoma cell lines, HepG2 and Hep3B cells. HepG2 cells were more sensitive to 10058-F4 than Hep3B cells, as demonstrated by reduced cell viability, marked morphological changes and decreased c-Myc levels. 10058-F4 arrested the cell cycle (at G0/G1 phase) and induced apoptosis upon extended treatment. These observations might be attributable to the increased cyclin-dependent kinase inhibitor, p21, and decreased cyclin D3 levels. Besides, 10058-F4 also significantly decreased the alpha-fetoprotein levels, an indicator for hepatocellular carcinoma differentiation. We further found that 10058-F4 inhibited the transactivation of human telomerase reverse transcriptase, downregulated human telomerase reverse transcriptase expression and abrogated telomerase activity. In addition, pretreatment with 10058-F4 increased the chemosensitivity of HepG2 cells to low-dose doxorubicin, 5-fluorouracil and cisplatin. Therefore, small-molecule c-Myc inhibitors might represent a novel agent, alone or in combination with conventional chemotherapeutic agents, for anti-hepatocellular carcinoma therapy. ------>tmu_sno=None ------>sno=14381 ------>authors2=Liu JD ------>authors3=Chow JM ------>authors4=Liu CR ------>authors5=Liu HE ------>authors6= ------>authors6_c= ------>authors=Lin CP ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=??? ------>publish_area=0 ------>updateTitle=Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=2 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2007 ------>submit_flag=None ------>publish_month=2 |